While the condition can impact quality of life and mental health, seeking treatment and support can make a powerful ...

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of artificial intelligence (AI)-based solutions for skin is excited to announce the publication of a case study highlighting the use of ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing CohortInterim Data from Atopic Dermatitis Trial ...

Enveda, a biotechnology company using AI to translate nature into new medicines, announced today that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) ...

In one study, ChatGPT information on atopic dermatitis received a score of 3.46/5 from physicians assessing its concordance with clinical guidelines. ChatGPT treatment recommendations for atopic ...

Vernal keratoconjunctivitis (VKC) is an ocular disorder characterized by severe inflammation affecting both the cornea and ...

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, announced ...

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.

The firm is highly encouraged by management’s enthusiasm for the upcoming atopic dermatitis readout in December. Cash remains constrained given the level of clinical activity, with Q3-ending cash ...